Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah H. Charych, Jonathan Zalevsky, Peter Kirk et al.|PLoS ONE|2017Cited by 145
Abstract 1617: Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacologySamira Khalili, Ute Hoch, Deborah H. Charych et al.|Cancer Research|2017Cited by 0